Here are three points:
1. The groups will develop a pair of antibodies to prevent and treat MERS.
2. HHS will allot $8.9 million to Regeneron for manufacturing, the investigational new drug application and an National Institutes of Health clinical trial.
3. Currently, no drugs exist to treat or prevent MERS.
More articles on quality & infection control:
The benefits of a team-based approach to ASC infection control compliance
5 things to know about the global over-the-counter drug market
How to effectively communicate adverse events to family members — 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
